secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2026-05-13T20:03:30+00:00
Accession:  0001628280-26-034583
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Q1 net loss $42.6M; ALPHA3 interim shows 58% MRD clearance; cash runway extended to Q1 2029
--------------------------------------------------------------------------------

- Terminated exclusive license with Overland; retains ~3% equity; no termination payments.
- ALPHA3 interim: 58.3% MRD clearance in cema-cel arm vs 16.7% observation; no CRS/ICANS/GvHD.
- Q1 net loss $42.6M ($0.18/sh); operating cash expense guidance raised to ~$165M.
- Cash $266.9M; April public offering grossed $200.4M; runway into Q1 2029.
- ALLO-329 Phase 1 RESOLUTION dosed 9 patients; initial signs of activity; next update Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000162828026034583/0001628280-26-034583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000162828026034583/allo-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-034583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer